Article in Molecular imaging and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors.
Cristina SimóDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Alexander C VanoverDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
E Carmen AzevedoDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Patrícia M R PereiraDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA. ribeiropereirap@wustl.edu.ORCID 0000-0002-4772-9339
Funding
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatinR01CA244233 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JANJIGIAN, YELENA Y, LEWIS, JASON S. · 2021 to 2025
$3.4M
Reversing Drug Resistance in Tumors with Clickable Antibody PairsR37CA276498 · NCI · WASHINGTON UNIVERSITY · PI Patricia Manuela Ribeiro Pereira · 2023 to 2026
$2.5M
Acquisition of high-resolution PET/CT preclinical imaging instrument at MIRS10OD030403 · OD · WASHINGTON UNIVERSITY · PI SHOGHI, KOORESH ISAAC · 2021 to 2021
$929k
S1PR1-targeted PET imaging to predict and monitor response to HER2-targeting antibody-drug conjugatesR21CA291680 · NCI · WASHINGTON UNIVERSITY · PI RIBEIRO PEREIRA, PATRICIA MANUELA, TU, ZHUDE · 2024 to 2024
Radiopharmaceuticals based on antibody biomolecules are widely used in oncology for positron emission tomography (PET). Trastuzumab, an antibody that targets the epidermal growth factor receptor 2 (HER2), has been extensively studied for both preclinical and clinical cancer imaging. This MIB guide specifically focuses on the radiolabeling of the antibody trastuzumab with zirconium-89 (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.